header logo image

First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

October 17th, 2020 4:24 pm

TORONTO, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.

More here:
First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick